Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 3.2% in the afternoon session after ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit exceeding Wall Street’s expectations. Management attributed the ...

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They ...

The botulinum toxin market is projected to grow at a CAGR of approximately 10% from 2025 to 2030. This growth is driven by ...

The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage ...

More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real world impacts, among other things, can help, explains Bennett Smith.

The number of employees laid off and companies letting people go increased year over year during the first half of 2025.

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.